SB 612111 hydrochlorideSelective NOP receptor antagonist CAS# 371980-94-8 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 371980-94-8 | SDF | Download SDF |
PubChem ID | 21061234 | Appearance | Powder |
Formula | C24H30Cl3NO | M.Wt | 454.86 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in DMSO and to 100 mM in ethanol | ||
Chemical Name | (5S,7S)-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-1-methyl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-ol;hydrochloride | ||
SMILES | CC1=CC=CC2=C1CCC(CC2O)CN3CCC(CC3)C4=C(C=CC=C4Cl)Cl.Cl | ||
Standard InChIKey | DCKUVQADDNMWEF-DQFHVVJASA-N | ||
Standard InChI | InChI=1S/C24H29Cl2NO.ClH/c1-16-4-2-5-20-19(16)9-8-17(14-23(20)28)15-27-12-10-18(11-13-27)24-21(25)6-3-7-22(24)26;/h2-7,17-18,23,28H,8-15H2,1H3;1H/t17-,23-;/m0./s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Selective NOP receptor antagonist (Ki values are 0.33, 57.6, 160.5 and 2109 nM for NOP, μ-, κ- and δ-receptors respectively). Antagonizes the pronociceptive action of nociceptin in an acute pain model. Potentiates the action of morphine in morphine-tolerant animals and blocks hyperalgesia in an inflammatory pain model. |
SB 612111 hydrochloride Dilution Calculator
SB 612111 hydrochloride Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.1985 mL | 10.9924 mL | 21.9848 mL | 43.9696 mL | 54.962 mL |
5 mM | 0.4397 mL | 2.1985 mL | 4.397 mL | 8.7939 mL | 10.9924 mL |
10 mM | 0.2198 mL | 1.0992 mL | 2.1985 mL | 4.397 mL | 5.4962 mL |
50 mM | 0.044 mL | 0.2198 mL | 0.4397 mL | 0.8794 mL | 1.0992 mL |
100 mM | 0.022 mL | 0.1099 mL | 0.2198 mL | 0.4397 mL | 0.5496 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- ZAPA sulfate
Catalog No.:BCC6563
CAS No.:371962-01-5
- YM201636
Catalog No.:BCC4996
CAS No.:371942-69-7
- PI-103 Hydrochloride
Catalog No.:BCC1860
CAS No.:371935-79-4
- PI-103
Catalog No.:BCC1162
CAS No.:371935-74-9
- Flavoxate hydrochloride
Catalog No.:BCC5208
CAS No.:3717-88-2
- 4'-Amino-3',5'-dichloroacetophenone
Catalog No.:BCC8678
CAS No.:37148-48-4
- Murrangatin
Catalog No.:BCN5426
CAS No.:37126-91-3
- IC-87114
Catalog No.:BCC1161
CAS No.:371242-69-2
- Azlocillin sodium salt
Catalog No.:BCC4763
CAS No.:37091-65-9
- Procyanidin C1
Catalog No.:BCN6317
CAS No.:37064-30-5
- Z-Glu-OBzl
Catalog No.:BCC2780
CAS No.:3705-42-8
- Cyclo(Gly-L-Pro)
Catalog No.:BCN4059
CAS No.:3705-27-9
- L-Citruline
Catalog No.:BCN2692
CAS No.:372-75-8
- Capsidiol
Catalog No.:BCC8140
CAS No.:37208-05-2
- Citromycin
Catalog No.:BCN7459
CAS No.:37209-30-6
- PIK-75
Catalog No.:BCC1163
CAS No.:372196-77-5
- Sieber Linker
Catalog No.:BCC2835
CAS No.:3722-51-8
- Wilforgine
Catalog No.:BCN5427
CAS No.:37239-47-7
- Wilfortrine
Catalog No.:BCN3085
CAS No.:37239-48-8
- Wilfordine
Catalog No.:BCN3083
CAS No.:37239-51-3
- TCS OX2 29
Catalog No.:BCC7670
CAS No.:372523-75-6
- Sennoside C
Catalog No.:BCN1004
CAS No.:37271-16-2
- Sennoside D
Catalog No.:BCN1005
CAS No.:37271-17-3
- H-D-Tyr-OMe.HCl
Catalog No.:BCC3135
CAS No.:3728-20-9
Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrah ydro-5H-benzocyclohepten-5-ol]: in vivo studies.[Pubmed:17329551]
J Pharmacol Exp Ther. 2007 Jun;321(3):968-74.
The excellent pharmacological profile displayed by the selective nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrah ydro-5H-benzocyclohepten-5-ol] in vitro prompted us to investigate the actions of this compound in vivo. In the mouse tail withdrawal assay, SB-612111 given i.p. up to 3 mg/kg did not modify per se tail withdrawal latencies but was able to prevent the pronociceptive and the antinociceptive action of 1 nmol of N/OFQ given i.c.v. and i.t., respectively. In food intake studies performed in sated mice, SB-612111 (1 mg/kg i.p.) had no effect on food consumption but fully prevented the orexigenic effect of 1 nmol of N/OFQ i.c.v. In 17-h food-deprived mice, the opioid receptor antagonist naltrexone (1 mg/kg s.c.), but not SB-612111 (1 and 10 mg/kg i.p.), produced a statistically significant reduction of food intake. In the mouse forced swimming and tail suspension tests, SB-612111 (1-10 mg/kg) reduced immobility time. The antidepressant-like effect elicited by SB-612111 in the forced swimming test was reversed by the i.c.v. injection of 1 nmol of N/OFQ and no longer evident in mice knockout for the NOP receptor gene. In conclusion, the present findings demonstrate that SB-612111 behaves in vivo as a potent and selective NOP antagonist and suggest that the N/OFQ-NOP receptor endogenous system plays an important role in regulating mood-related behaviors. The use of SB-612111 in future pathophysiological studies will certainly contribute to define the therapeutic potential of selective NOP receptor antagonists in different disease areas.
Modification of nociception and morphine tolerance by the selective opiate receptor-like orphan receptor antagonist (-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahy dro-5H-benzocyclohepten-5-ol (SB-612111).[Pubmed:14593080]
J Pharmacol Exp Ther. 2004 Feb;308(2):454-61.
(-)-cis-1-Methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahy dro-5H-benzocyclohepten-5-ol (SB-612111) is a novel human opiate receptor-like orphan receptor (ORL-1) antagonist that has high affinity for the clonal human ORL-1 receptor (hORL-1 K(i) = 0.33 nM), selectivity versus mu-(174-fold), delta-(6391-fold), and kappa (486-fold)-opioid receptors and is able to inhibit nociceptin signaling via hORL-1 in a whole cell gene reporter assay. SB-612111 has no measurable antinociceptive effects in vivo in the mouse hot-plate test after intravenous administration but is able to antagonize the antimorphine action of nociceptin [ED(50) = 0.69 mg/kg, 95% confidence limit (CL) = 0.34-1.21]. SB-62111 administration can also reverse tolerance to morphine in this model, established via repeated morphine administration. In addition, intravenous SB-612111 can antagonize nociceptin-induced thermal hyperalgesia in a dose-dependent manner (ED(50) = 0.62 mg/kg i.v., 95% CL = 0.22-1.89) and is effective per se at reversing thermal hyperalgesia in the rat carrageenan inflammatory pain model. These data show that an ORL-1 receptor antagonist may be a useful adjunct to chronic pain therapy with opioids and can be used to treat conditions in which thermal hyperalgesia is a significant component of the pain response.